TPO and autoimmune thrombocytopenic purpura: The clinical application of TPO in the treatment of primary immune thrombocytopenic purpura (ITP) achieved a definite therapeutic effect and had become the first-line recommended treatment.[14] The most representative platelet growth-promoting factor available in China is rhTPO.